Complix, a Hasselt (Belgium)-based biopharmaceutical company focused on the discovery and development of a class of protein therapeutics active against intracellular disease targets, closed a €12m (approximately US$15.5m) Series B equity financing.
The round was co-led by new investors Edmond de Rothschild Investment Partners (France) and Gimv (Belgium) and Biotech Fund Flanders (managed by Gimv), with participation from existing shareholders LRM, OMNES Capital, Vesalius Biocapital, Gemma Frisius Fund, TrustCapital, Vinnof, Baekeland Fund, CRP-Santé and management. In conjunction with the funding, Mr Gilles Nobécourt from Edmond de Rothschild Investment Partners and Mr Patrick Van Beneden from Gimv will join Complix’ Board of Directors, along with industry expert Professor Thierry Hercend, MD, PhD.
Led by Dr Mark Vaeck, CEO, Complix is developing Alphabodies, a bio-therapeutic platform with the capacity to address a vast number of disease targets that are currently considered “undruggable” by the two main classes of therapeutics: small chemical drugs and therapeutic antibodies.
Alphabodies are a new class of protein therapeutics that combine the features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs, such as stability and their capacity to penetrate cells.
The company intends to use the funds to develop therapeutic Alphabodies for treatment of cancer and autoimmune indications, and to further expand and validate its Alphabody platform.
Based in the Life Sciences incubator BioVille, Complix has research facilities in Ghent (Belgium) and Luxembourg (where it has a fully owned subsidiary.
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group which is specialized in asset management and private banking (€130bn under management, 2,900 employees and 30 offices throughout the world). Founded in 1953, the Group has been chaired since 1997 by the founder’s son, Baron Benjamin de Rothschild.
Edmond de Rothschild Investment Partners is dedicated to making minority investments in privately-owned companies. It has currently close to €1 billion under management which is being invested primarily as life sciences venture capital and growth capital.
Its Life Sciences Team of eight professionals has over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team has €355 million under management through its Biodiscovery franchise. BioDiscovery Funds, including BioDiscovery 4, are venture capital funds registered via the fast-track procedure. These funds are not authorized by the Autorité des marchés financiers and may adopt special investment rules.
BioDiscovery 4, a Capital Venture Funds registered via the fast-track procedure, invests mainly in private companies, which involves specific risks such as a risk of capital loss, a discretionary management risk and a liquidity risk.
For more information please visit: http://www.edrip.fr.
Gimv is a European investment company with over three decades’ experience in private equity and venture capital. Gimv is listed on NYSE Euronext Brussels and currently manages around €1.8 billion (including third party funds) of investments in 75 portfolio companies, which in aggregate generate and annual turnover of over €6 billion and employ over 26,000 professionals.
As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.
For more information please visit: http://www.gimv.be.
About Biotech Fund Flanders
The Gimv managed Biotech Fonds Vlaanderen (BFV) is a venture capital fund for co-investment in the biotech sector in Flanders. It was set up in 1994 and is funded by the Flemish government. The fund provides seed and growth capital to new and existing biotech companies in Flanders, and as a result has played a key role in building Flanders into a reputable global player in scientific research and industrial development. BFV has already invested about €90 million in more than 19 biotech companies, a number of which are now listed.
Dr. Mark Vaeck, CEO